Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of AZD5004 in healthy Japanese adults and Japanese adults with type 2 diabetes mellitus
jRCT2051240164Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of elecoglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoint: AZD5004 safety parameters. Started Nov 2024; status: active, not recruiting.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2051240164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240164.